Coherus BioSciences, Inc., a biosimilar company, develops and commercializes various therapeutic products worldwide. The company engages in the development of late-stage clinical products, including CHS-1701 pegfilgrastim biosimilar, a granulocyte colony-stimulating factor product candidate; CHS-1420 adalimumab biosimilar, an anti-tumor necrosis factor product candidate; and CHS-0214, an etanercept biosimilar for rheumatoid arthritis and psoriasis. It is also developing a pipeline of products in therapeutic areas, such as oncology, immunology, and ophthalmology comprising CHS-3351, a ranibizumab biosimilar; and CHS-2020, an aflibercept biosimilar, as well as CHS-131, a small molecule for multiple sclerosis. Coherus BioSciences, Inc. has license agreement with Selexis SA and Genentech, Inc. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [03/08/2018 12:16 PST] Coherus BioSciences, Inc. (NASDAQ:CHRS), Down By 8.33% ($0.80) From $9.600 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [03/07/2018 06:38 PST] CHRS Expected to Trade Down Short Term
• [02/27/2018 12:36 PST] Coherus BioSciences, Inc. (NASDAQ:CHRS), Up By 13.64% ($1.35) From $9.900 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [02/26/2018 14:56 PST] Coherus BioSciences, Inc. (NASDAQ:CHRS), Up By 5.56% ($0.55) From $9.900 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions